Indications and uses
helps prevent sunburn if used as directed with other sun protection measures (see Directions ), decreases the risk of skin cancer and early skin aging caused by the sun
CLE DE PEAU BEAUTE FOUNDATION I
- Manufacturer
- SHISEIDO CO., LTD.
- Effective date
- 2012-04-11
- Label type
- HUMAN OTC DRUG LABEL
- Version
- 2
- Source
- legacy-cache
- Hydrated at
- 2026-08-02 01:47:42
Label at a glance#
ProductCLE DE PEAU BEAUTE FOUNDATION I BF20
Active ingredientTitanium dioxide
Label structure18 sections
Dosage and administration
For sunscreen use: apply liberally 15 minutes before sun exposure use a water resistant sunscreen if swimming or sweating reapply at least every 2 hours Sun Protection Measures . Spending time in the sun increases your risk of skin cancer and early skin aging. To decrease this risk, regularly use a sunscreen with a broad spectrum SPF of 15 or higher and other sun protection measures including: limit time in the su...
Storage and handling
protect this product in this container from excessive heat and direct sun.
Contacts and useful links#
Label contents#
Full prescribing information#
SPL UNCLASSIFIED SECTION
Drug Facts
Active ingredient
TITANIUM DIOXIDE 2.1%
Purpose
Sunscreen
Uses
- helps prevent sunburn
- if used as directed with other sun protection measures (see Directions), decreases the risk of skin cancer and early skin aging caused by the sun
Warnings
For external use only
OTC - DO NOT USE SECTION
Do not use on damaged or broken skin
OTC - WHEN USING SECTION
When using this product keep out of eyes. Rinse with water to remove.
OTC - STOP USE SECTION
Stop use and ask a doctor if rash occurs
OTC - KEEP OUT OF REACH OF CHILDREN SECTION
Keep out of reach of children. If product is swallowed, get medical help or contact a Poison Control Center right away.
Directions
For sunscreen use:
- apply liberally 15 minutes before sun exposure
- use a water resistant sunscreen if swimming or sweating
- reapply at least every 2 hours
- Sun Protection Measures. Spending time in the sun increases your risk of skin cancer and early skin aging. To decrease this risk, regularly use a sunscreen with a broad spectrum SPF of 15 or higher and other sun protection measures including:
- limit time in the sun, especially from 10 a.m. – 2 p.m.
- wear long-sleeve shirts, pants, hats, and sunglasses
- children under 6 months: Ask a doctor
Inactive Ingredients
WATER • CYCLOMETHICONE • TALC • BUTYLENE GLYCOL • NYLON-12 • DIMETHICONE • GLYCERIN • PEG-10 DIMETHICONE • DEXTRIN PALMITATE • BARIUM SULFATE • POLYMETHYL METHACRYLATE • TOCOPHERYL ACETATE • GINKGO BILOBA LEAF EXTRACT • SODIUM ACETYLATED HYALURONATE • ROSA ROXBURGHII FRUIT EXTRACT • LILIUM CANDIDUM BULB EXTRACT • ALUMINUM HYDROXIDE • PALMITIC ACID • STEARIC ACID • TRISODIUM EDTA • DISTEARYLDIMONIUM CHLORIDE • VINYL DIMETHICONE/METHICONE SILSESQUIOXANE CROSSPOLYMER • POLYSILICONE-2 • ISOPROPYL ALCOHOL • SYNTHETIC FLUORPHLOGOPITE • TOCOPHEROL • TRIETHOXYSILYLETHYL POLYDIMETHYLSILOXYETHYL DIMETHICONE • PHENOXYETHANOL • FRAGRANCE • TITANIUM DIOXIDE • IRON OXIDES • MICA •
Other information
- protect this product in this container from excessive heat and direct sun.
Questions or comments?
Call toll free 1-800-906-7503
SPL UNCLASSIFIED SECTION
Manufactured by
SHISEIDO CO., LTD.
7-5-5 GINZA TOKYO
PRINCIPAL DISPLAY PANEL - 25 mL Tube Carton - BF20
clé de peau
BEAUTÉ
cream foundation
BROAD SPECTRUM SPF 29
SUNSCREEN
25mL NET WT. 1.1 OZ.
PRINCIPAL DISPLAY PANEL - 25 mL Tube Carton - I10
clé de peau
BEAUTÉ
cream foundation
BROAD SPECTRUM SPF 29
SUNSCREEN
25mL NET WT. 1.1 OZ.
PRINCIPAL DISPLAY PANEL - 25 mL Tube Carton - O10
clé de peau
BEAUTÉ
cream foundation
BROAD SPECTRUM SPF 29
SUNSCREEN
25mL NET WT. 1.1 OZ.
PRINCIPAL DISPLAY PANEL - 25 mL Tube Carton - O20
clé de peau
BEAUTÉ
cream foundation
BROAD SPECTRUM SPF 29
SUNSCREEN
25mL NET WT. 1.1 OZ.
PRINCIPAL DISPLAY PANEL - 25 mL Tube Carton - O30
clé de peau
BEAUTÉ
cream foundation
BROAD SPECTRUM SPF 29
SUNSCREEN
25mL NET WT. 1.1 OZ.
PRINCIPAL DISPLAY PANEL - 25 mL Tube Carton - B10
clé de peau
BEAUTÉ
cream foundation
BROAD SPECTRUM SPF 29
SUNSCREEN
25mL NET WT. 1.1 OZ.
PRINCIPAL DISPLAY PANEL - 25 mL Tube Carton - B20
clé de peau
BEAUTÉ
cream foundation
BROAD SPECTRUM SPF 29
SUNSCREEN
25mL NET WT. 1.1 OZ.
PRINCIPAL DISPLAY PANEL - 25 mL Tube Carton - B30
clé de peau
BEAUTÉ
cream foundation
BROAD SPECTRUM SPF 29
SUNSCREEN
25mL NET WT. 1.1 OZ.
FDA-Initiated Inactive NDC Indexing#
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| Titanium dioxide | ACTIVE INGREDIENT | 15FIX9V2JP | 2 | |
| Titanium dioxide | ACTIVE MOIETY | 15FIX9V2JP | 2 | |
| .ALPHA.-TOCOPHEROL | INACTIVE INGREDIENT | H4N855PNZ1 | 2 | |
| .ALPHA.-TOCOPHEROL ACETATE, DL- | INACTIVE INGREDIENT | WR1WPI7EW8 | 2 | |
| ALUMINUM HYDROXIDE | INACTIVE INGREDIENT | 5QB0T2IUN0 | 2 | |
| BARIUM SULFATE | INACTIVE INGREDIENT | 25BB7EKE2E | 2 | |
| BUTYLENE GLYCOL | INACTIVE INGREDIENT | 3XUS85K0RA | 2 | |
| CYCLOMETHICONE | INACTIVE INGREDIENT | NMQ347994Z | 2 | |
| DIMETHICONE | INACTIVE INGREDIENT | 92RU3N3Y1O | 2 | |
| DISTEARYLDIMONIUM CHLORIDE | INACTIVE INGREDIENT | OM9573ZX3X | 2 | |
| EDETATE TRISODIUM | INACTIVE INGREDIENT | 420IP921MB | 2 | |
| FERRIC OXIDE RED | INACTIVE INGREDIENT | 1K09F3G675 | 2 | |
| FERRIC OXIDE YELLOW | INACTIVE INGREDIENT | EX438O2MRT | 2 | |
| FERROSOFERRIC OXIDE | INACTIVE INGREDIENT | XM0M87F357 | 2 | |
| GINKGO | INACTIVE INGREDIENT | 19FUJ2C58T | 2 | |
| GLYCERIN | INACTIVE INGREDIENT | PDC6A3C0OX | 2 | |
| ISOPROPYL ALCOHOL | INACTIVE INGREDIENT | ND2M416302 | 2 | |
| LILIUM CANDIDUM BULB | INACTIVE INGREDIENT | AHG15J8AM0 | 2 | |
| MICA | INACTIVE INGREDIENT | V8A1AW0880 | 2 | |
| NYLON-12 | INACTIVE INGREDIENT | 446U8J075B | 2 | |
| PALMITIC ACID | INACTIVE INGREDIENT | 2V16EO95H1 | 2 | |
| PEG-10 DIMETHICONE (600 CST) | INACTIVE INGREDIENT | 8PR7V1SVM0 | 2 | |
| PHENOXYETHANOL | INACTIVE INGREDIENT | HIE492ZZ3T | 2 | |
| ROSA ROXBURGHII FRUIT | INACTIVE INGREDIENT | CVT1AA87FF | 2 | |
| STEARIC ACID | INACTIVE INGREDIENT | 4ELV7Z65AP | 2 | |
| TALC | INACTIVE INGREDIENT | 7SEV7J4R1U | 2 | |
| TITANIUM DIOXIDE | INACTIVE INGREDIENT | 15FIX9V2JP | 2 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 2 |
Products#
Every source-derived product name is available through these pages.
- CLE DE PEAU BEAUTE FOUNDATION I BF20
- Titanium dioxide
- WATER
- CYCLOMETHICONE
- TALC
- BUTYLENE GLYCOL
- NYLON-12
- DIMETHICONE
- GLYCERIN
- PEG-10 DIMETHICONE (600 CST)
- FERRIC OXIDE RED
- FERRIC OXIDE YELLOW
- FERROSOFERRIC OXIDE
- BARIUM SULFATE
- ALUMINUM HYDROXIDE
- PHENOXYETHANOL
- PALMITIC ACID
- STEARIC ACID
- EDETATE TRISODIUM
- DISTEARYLDIMONIUM CHLORIDE
- MICA
- .ALPHA.-TOCOPHEROL ACETATE, DL-
- ISOPROPYL ALCOHOL
- GINKGO
- ROSA ROXBURGHII FRUIT
- .ALPHA.-TOCOPHEROL
- LILIUM CANDIDUM BULB
- CLE DE PEAU BEAUTE FOUNDATION I I10
- CLE DE PEAU BEAUTE FOUNDATION I O10
- CLE DE PEAU BEAUTE FOUNDATION I O20
- CLE DE PEAU BEAUTE FOUNDATION I O30
- CLE DE PEAU BEAUTE FOUNDATION I B10
- CLE DE PEAU BEAUTE FOUNDATION I B20
- CLE DE PEAU BEAUTE FOUNDATION I B30
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 52685-338 | 52685-338-60 |
| 52685-339 | 52685-339-60 |
| 52685-340 | 52685-340-60 |
| 52685-341 | 52685-341-60 |
| 52685-342 | 52685-342-60 |
| 52685-343 | 52685-343-60 |
| 52685-344 | 52685-344-60 |
| 52685-345 | 52685-345-60 |
Ingredients#
Every source-derived ingredient row is available through these pages.
Source Document#
Inactive ingredient matches#
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SYRUP / ORAL | 16734 mg | ||
| FERRIC OXIDE RED | FERRIC OXIDE RED | 1K09F3G675 | CAPSULE, COATED PELLETS / ORAL | 2 mg | ||
| STEARIC ACID | STEARIC ACID | 4ELV7Z65AP | TABLET / SUBLINGUAL | 9 mg | ||
| ISOPROPYL ALCOHOL | ISOPROPYL ALCOHOL | ND2M416302 | SWAB / TOPICAL | 43.9 %w/w | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | POWDER / RESPIRATORY (INHALATION) | 2 mg | ||
| TALC | TALC | 7SEV7J4R1U | ELIXIR / ORAL | 4.5 mg/5ml | ||
| FERROSOFERRIC OXIDE | FERROSOFERRIC OXIDE | XM0M87F357 | CAPSULE, EXTENDED RELEASE / ORAL | 1.49 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | TABLET, COATED / ORAL | 1 mg | ||
| FERRIC OXIDE RED | FERRIC OXIDE RED | 1K09F3G675 | TABLET, DELAYED RELEASE / ORAL | 37 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | SUSPENSION / ORAL | 113 mg | ||
| FERRIC OXIDE YELLOW | FERRIC OXIDE YELLOW | EX438O2MRT | FILM / BUCCAL | 0.27 mg | ||
| FERRIC OXIDE RED | FERRIC OXIDE RED | 1K09F3G675 | TABLET, EXTENDED RELEASE / ORAL | 7 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION/ DROPS / OPHTHALMIC | 12 mg | ||
| TALC | TALC | 7SEV7J4R1U | TABLET / ORAL | 1000 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | LOTION / TOPICAL | 3990 mg | ||
| FERRIC OXIDE YELLOW | FERRIC OXIDE YELLOW | EX438O2MRT | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL | 2 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | FILM, EXTENDED RELEASE / TRANSDERMAL | 306.2 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOAP / TOPICAL | 0.76 %w/w | ||
| PALMITIC ACID | PALMITIC ACID | 2V16EO95H1 | INJECTION, POWDER, FOR SUSPENSION / INTRAVENOUS | NA | ||
| EDETATE TRISODIUM | EDETATE TRISODIUM | 420IP921MB | CREAM / TOPICAL | NA | ||
| FERRIC OXIDE YELLOW | FERRIC OXIDE YELLOW | EX438O2MRT | GRANULE, FOR SUSPENSION / ORAL | 11 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | PASTE / DENTAL | 20 %w/w | ||
| FERRIC OXIDE YELLOW | FERRIC OXIDE YELLOW | EX438O2MRT | TABLET / SUBLINGUAL | 1 mg | ||
| TALC | TALC | 7SEV7J4R1U | PELLET / ORAL | 69 mg | ||
| TALC | TALC | 7SEV7J4R1U | CAPSULE, DELAYED RELEASE / ORAL | 420 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | GEL / OPHTHALMIC | 0.88 %w/w | ||
| TALC | TALC | 7SEV7J4R1U | SUSPENSION / ORAL | 234 mg | ||
| TALC | TALC | 7SEV7J4R1U | CAPSULE, EXTENDED RELEASE / ORAL | 5119 mg | ||
| PHENOXYETHANOL | PHENOXYETHANOL | HIE492ZZ3T | CREAM, AUGMENTED / TOPICAL | 10 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | CLOTH / TOPICAL | 0.05 mg/mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | GUM, CHEWING / BUCCAL | 230 mg | ||
| FERRIC OXIDE RED | FERRIC OXIDE RED | 1K09F3G675 | TABLET / BUCCAL | 0.4 mg | ||
| ALUMINUM HYDROXIDE | ALUMINUM HYDROXIDE | 5QB0T2IUN0 | OINTMENT / TOPICAL | NA | ||
| FERRIC OXIDE YELLOW | FERRIC OXIDE YELLOW | EX438O2MRT | POWDER, FOR SUSPENSION / ORAL | 3 mg | ||
| ISOPROPYL ALCOHOL | ISOPROPYL ALCOHOL | ND2M416302 | SOLUTION / TOPICAL | 40 %w/v | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | FILM / BUCCAL | 3 mg | ||
| FERRIC OXIDE YELLOW | FERRIC OXIDE YELLOW | EX438O2MRT | TABLET, CHEWABLE / ORAL | 14 mg | ||
| FERROSOFERRIC OXIDE | FERROSOFERRIC OXIDE | XM0M87F357 | TABLET, COATED / ORAL | NA | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SPONGE / TOPICAL | 2 %w/w | ||
| CYCLOMETHICONE | CYCLOMETHICONE | NMQ347994Z | CREAM, AUGMENTED / TOPICAL | 7.6 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION, CONCENTRATE / ORAL | 200 mg/1ml | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION / INTRAVENOUS | 33750 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | CREAM / VAGINAL | 60 mg | ||
| ISOPROPYL ALCOHOL | ISOPROPYL ALCOHOL | ND2M416302 | TABLET, EXTENDED RELEASE / ORAL | NA | ||
| FERRIC OXIDE RED | FERRIC OXIDE RED | 1K09F3G675 | DROPS / ORAL | NA | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | LIQUID / TOPICAL | 2.5 %w/w | ||
| STEARIC ACID | STEARIC ACID | 4ELV7Z65AP | TABLET / ORAL | 336 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL | 42 mg | ||
| STEARIC ACID | STEARIC ACID | 4ELV7Z65AP | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 120 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | SHAMPOO, SUSPENSION / TOPICAL | 3 %w/v | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | CAPSULE, LIQUID FILLED / ORAL | 185 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION, SOLUTION / INTRAMUSCULAR | 15 %w/v | ||
| ISOPROPYL ALCOHOL | ISOPROPYL ALCOHOL | ND2M416302 | LOTION, AUGMENTED / TOPICAL | 2070 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION, EMULSION / INTRAVENOUS | 24100 mg | ||
| FERROSOFERRIC OXIDE | FERROSOFERRIC OXIDE | XM0M87F357 | CAPSULE, COATED / ORAL | 0.11 mg | ||
| FERRIC OXIDE YELLOW | FERRIC OXIDE YELLOW | EX438O2MRT | TABLET, EXTENDED RELEASE / ORAL | 15 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 225 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | TABLET, CHEWABLE / ORAL | 12 mg | ||
| STEARIC ACID | STEARIC ACID | 4ELV7Z65AP | CAPSULE / ORAL | 90 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | EMULSION / INTRAVENOUS | 2.2 %w/v |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 2e979c88-4fc2-4940-aeed-61afeb5cd0b0 | d6c57a21-19ec-41ba-adaa-a7873482ee32 | 2023-09-22 | Warnings | d6c57a21-19ec-41ba-adaa-a7873482ee32 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.